Clinical Trial Update: Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating weekly docetaxel and bortezomib for advanced hormone-refractory prostate cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Docetaxel (Taxotere) (docetaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED